Delving into the Latest Updates on Betamethasone Acetate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Betamethasone acetate (JAN/USP)

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Skin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

Vitiligo

Originator Organization

Jiangsu Lingbao Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Jiangsu Lingbao Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhaseWithdrawn

First Approval Date

China (01 Jan 1985),

Vitiligo

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H31FO6

InChIKeyAKUJBENLRBOFTD-QZIXMDIESA-N

CAS Registry987-24-6

Pulmonary sarcoidosis (PS) is an immune-mediated disorder characterised by a significant association with various immune cell types including macrophages, T-helper 1 (TH1) cells, and TH17 cells. Dysregulation of immune cell differentiation leads to pronounced inflammatory responses in the pulmonary system, resulting in granuloma formation. Currently, the therapeutic approach for PS predominantly involves the use of immunosuppressive agents. However, the considerable adverse effects associated with these treatments underscore the urgent need to develop novel anti-PS pharmacological interventions.

PURPOSE:

To investigate whether essential oil from Radix Curcumae (RCEO) improves pulmonary function in PS mice by inhibiting inflammation mediated by the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa-B (NF-κB) (TLR4/MyD88/NF-κB) pathway.

METHODS:

Bioinformatics and network pharmacology methodologies were used to predict potential therapeutic targets of RCEO in the context of PS. The primary components of RCEO were analysed using gas chromatography-mass spectrometry. A murine model of PS was established by induction with Propionibacterium acnes, and alterations in pulmonary function were evaluated using whole-body plethysmography. An enzyme-linked immunosorbent assay was used to measure changes in inflammatory mediators in the blood and bronchoalveolar lavage fluid. Additionally, flow cytometry was performed to determine the differentiation of CD4+ T cells into TH1 and TH17 subsets in the lung tissues of mice in the model group. Immunofluorescence analysis was used to quantify the differentiation of macrophages into M1 and M2 phenotypes in the lung tissues. Polymerase chain reaction (PCR) and western blotting (WB) were used to assess alterations in the mRNAs expression levels and proteins associated with the TLR4/MyD88/NF-κB signalling pathway in pulmonary tissues.

RESULTS:

Bioinformatics and network pharmacology predictions suggested that the therapeutic effects of RCEO on PS are linked to the modulation of inflammation via the TLR4/MyD88/NF-κB pathway. In a murine model of PS, RCEO significantly reduced pathological alterations in lung tissue and enhanced pulmonary function. Subsequent experimental analyses revealed that RCEO inhibited the differentiation of macrophages into M1-type macrophages and reduced the differentiation of CD4+ T cells into TH1 and TH17 cells, thereby preventing granuloma formation in the mouse pulmonary tissue. Further PCR and WB analyses indicated that RCEO modulated immune cell differentiation by inhibiting inflammation mediated through the TLR4/MyD88/NF-κB signalling pathway. Immunofluorescence experiments demonstrated that RCEO conferred a protective effect against PS by attenuating inflammation in macrophages.

CONCLUSION:

RCEO inhibited the differentiation of macrophages into M1-type macrophages and suppressed the differentiation of CD4+T cells into TH1 and TH17 cells by blocking the inflammatory response mediated by the TLR4/MyD88/NF-κB pathway. This further reduced the formation of granulomas in lung tissue and improved lung function in PS mice.

01 Apr 2025·Journal of Environmental Chemical Engineering

Development of scalable cultivation strategy for microalgal biomass generation using wastewater and integrated biorefinery approach for biofuel production

Author: Jagadale, Krushna ; Tilva, Jeel ; Gawali, Sushant ; Singh, Bhaskar ; Guldhe, Abhishek ; Alam, Shahrukh Nawaj

Microalgal biomass production using wastewater (WW) is a sustainable approach for economically viable biorefinery.The present study aims to develop a scalable cultivation strategy using novel microalgae strain Marvania coccoides for biofuels productionThe cultivation strategy based on nutrient supplementation is developed at lab-scale (1 L) and validated at open-raceway pond system (200 L).Nutrient-supplemented wastewater (OWW) showed higher biomass productivity at both lab-scale (87.36 mg.L-1.d-1) and open pond system (133.89 mg.L-1.d-1) as compared to synthetic media.Biodiesel yield of 92.30 % was achieved upon transesterification of lipids from OWW (200 L) medium.Moreover, the residual biomass, i.e., lipid-extracted microalgal (LEM) biomass, yielded in 26.65 % of bio-oil and 56.94 % of biochar upon non-catalytic pyrolysis.Bio-oil and biochar produced were analyzed using element analyzer, gas chromatog.-mass spectrometry (GC-MS), and fourier-transform IR spectroscopy (FTIR).This scalable cultivation strategy for microalgae and biorefinery approach for production of biodiesel, bio-oil and biochar is sustainable solution for managing wastes and generation of biofuels.

01 Feb 2025·EYE

Uveitic macular oedema in ocular tuberculosis patients in a non-endemic country: characteristics, management, and visual Outcomes

Article

Author: Thiadens, Alberta A H J ; La Distia Nora, Rina ; Putera, Ikhwanuliman ; Rombach, Saskia M ; Larasmanah, Alamanda Siti Nurhasanah ; van Hagen, P Martin ; Ten Berge, Josianne C E M ; Dik, Willem A

OBJECTIVE:

To describe clinical features, treatment strategies and visual acuity changes of eyes with uveitic macular oedema (UMO) in ocular tuberculosis (OTB) patients from a non-TB-endemic country.

METHODS:

This retrospective study was conducted using a 10-year period registry of OTB patients diagnosed in Erasmus MC, Rotterdam. Longitudinal analysis of visual acuity trajectory in eyes with and without UMO was performed using linear mixed effect model.

RESULTS:

Out of 93 included patients, 23 (24.7%; 26 eye episodes) presented with baseline UMO. Older age (p = 0.024) and diabetes coexistence (p = 0.048) were associated with UMO. Eyes with baseline UMO showed lower presenting best-corrected visual acuity (BCVA) (p = 0.024). Posterior uveitis (p = 0.005), the presence of active vitreous cells (p = 0.016) and retinal vasculitis (p = 0.008) were ocular signs associated with UMO. A step-wise treatment approach primarily initiated with local steroids, followed by a combination with oral acetazolamide and, if necessary, additional systemic immunosuppressants. Overall, this approach resulted in complete UMO resolution in 77% (20/26) of cases. UMO resolution was shorter among eyes co-managed with ATT, although statistically not significant (p = 0.144). Eyes experiencing at least one UMO episode exhibited lower visual acuity at the last-follow-up than those without (p = 0.020).

CONCLUSIONS:

Active vitreous cells, retinal vasculitis and posterior uveitis are associated with UMO among OTB patients. The time-to-resolution of UMO for eyes co-managed with ATT was shorter compared to those without, suggesting that patients with UMO in OTB should be treated with ATT.

100 Deals associated with Betamethasone Acetate

Login to view more data